CVRx Inc CVRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
-
CVRx Announces Late-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026
-
CVRx Appoints John Landry as Chief Financial Officer
-
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CVRx, Inc. - CVRX
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims
-
HAGENS BERMAN, NATIONAL SECURITIES LAW FIRM, Encourages CVRx Inc. (CVRX) Investors with Substantial Losses to Contact Firm: Investigating Potential Securities Fraud Following 59% Stock Drop
-
CVRx Responds to Letter from Pointillist Family Office
Trading Information
- Previous Close Price
- $1.39
- Day Range
- $1.26–1.39
- 52-Week Range
- $1.26–11.30
- Bid/Ask
- $1.25 / $1.36
- Shares Outstanding
- 26.64M
- Market Cap
- $34.63M
- Volume/Avg
- 382,715 / 929,325
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.58
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 223
- Website
- https://www.cvrx.com
Valuation
|
Metric
|
CVRX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.82 |
Price/Sales | 0.58 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CVRX
|
|---|---|
Quick Ratio | 6.65 |
Current Ratio | 8.04 |
Interest Coverage | −7.62 |
Quick Ratio
CVRX
Profitability
|
Metric
|
CVRX
|
|---|---|
Return on Assets (Normalized) | −37.62% |
Return on Equity (Normalized) | −102.14% |
Return on Invested Capital (Normalized) | −36.24% |
Return on Assets
CVRX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|!^#%?t | LOCK|F?$Q | $181B | |||
| Medtronic PLC
MDT
| LOCK|X@#MW^ | LOCK|s#X@n | $121B | |||
| Stryker Corp
SYK
| LOCK|Gl<KZ&rw | LOCK|Pd> | $113B | |||
| Boston Scientific Corp
BSX
| LOCK|@>NZ@Q | LOCK|@X>Q | $64B | |||
| Edwards Lifesciences Corp
EW
| LOCK|&k^t%&P | LOCK|tN^D | $50B | |||
| DexCom Inc
DXCM
| LOCK|lj%M^WD | LOCK|R@hCx | $32B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|?xZ?%r> | LOCK|K! | $31B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|M^x | LOCK|JBf | $25B | |||
| Steris PLC
STE
| LOCK|^^x#^% | LOCK|gtgfl | $22B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|DBGJ$<@ | LOCK|>vx | $18B |
United States